These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27030277)

  • 1. Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration.
    Mansour AM; Chhablani J; Antonios RS; Yogi R; Younis MH; Dakroub R; Chahine H
    Br J Ophthalmol; 2016 Dec; 100(12):1629-1633. PubMed ID: 27030277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-month outcome of intravitreal ziv-aflibercept in eyes with diabetic macular oedema.
    Mansour AM; Dedhia C; Chhablani J
    Br J Ophthalmol; 2017 Feb; 101(2):166-169. PubMed ID: 27190127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziv-aflibercept in macular disease.
    Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
    Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    de Oliveira Dias JR; de Andrade GC; Kniggendorf VF; Novais EA; Maia A; Meyer C; Watanabe SES; Farah ME; Rodrigues EB
    Retina; 2017 Aug; 37(8):1499-1507. PubMed ID: 27798520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration.
    Sawada T; Wang X; Sawada O; Saishin Y; Ohji M
    Clin Exp Ophthalmol; 2018 Jan; 46(1):46-53. PubMed ID: 28621038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.
    Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal Ziv-Aflibercept: A Comprehensive Review.
    Barmas-Alamdari D; D'Souza HS; Kapoor KG; Wagner AL
    Semin Ophthalmol; 2019; 34(6):420-435. PubMed ID: 31314638
    [No Abstract]   [Full Text] [Related]  

  • 9. SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT.
    Chhablani J; Narayanan R; Mathai A; Yogi R; Stewart M
    Retina; 2016 Jun; 36(6):1126-31. PubMed ID: 26655620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
    Braimah IZ; Agarwal K; Mansour A; Chhablani J;
    Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT.
    Chhablani J; Dedhia CJ; Peguda HK; Stewart M
    Retina; 2017 Oct; 37(10):1859-1865. PubMed ID: 28060148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Visual and anatomical outcomes of three intravitreal aflibercept injections in eyes with neovascular form of age-related macular degeneration].
    Kałuiny JJ; Majer A; Jaworowska-Cieślińska I
    Klin Oczna; 2015; 117(1):9-13. PubMed ID: 26349151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.
    Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S
    BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H; Shah CP; Weber M; Heier JS
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration.
    Saito M; Kano M; Itagaki K; Sekiryu T
    Jpn J Ophthalmol; 2017 Jan; 61(1):74-83. PubMed ID: 27660164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year outcomes of intravitreal ziv-aflibercept.
    Mansour AM; Ashraf M; Charbaji A; Younis MH; Souka AA; Dogra A; Mansour HA; Chhablani J;
    Br J Ophthalmol; 2018 Oct; 102(10):1387-1390. PubMed ID: 29317400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy.
    Mansour AM; Charbaji A; Farah ME; Mansour HA; Chhablani J
    Br J Ophthalmol; 2019 Jul; 103(7):938-941. PubMed ID: 30072436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of ziv-aflibercept in retinal diseases.
    Mansour AM; Ashraf M; Dedhia CJ; Charbaji A; Souka AAR; Chhablani J
    Br J Ophthalmol; 2017 Oct; 101(10):1374-1376. PubMed ID: 28270485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.
    Matsumoto H; Hiroe T; Morimoto M; Mimura K; Ito A; Akiyama H
    Jpn J Ophthalmol; 2018 Mar; 62(2):144-150. PubMed ID: 29411171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLATTENING OF A TREATMENT-RESISTANT RETINAL PIGMENT EPITHELIAL DETACHMENT AFTER A SINGLE INTRAVITREAL INJECTION OF ZIV-AFLIBERCEPT.
    Yogi R; Stewart M; Chhablani J
    Retin Cases Brief Rep; 2017 Spring; 11(2):111-113. PubMed ID: 27078613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.